BridgeBio Pharma annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
BridgeBio Pharma Depreciation & Amortization Growth & History (BBIO)
BridgeBio Pharma's depreciation and amortization was $5.4M for fiscal 2025.
View full BridgeBio Pharma company overviewBridgeBio Pharma annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.4M | −$641,000 | −10.55% |
| 2024 | 2024-12-31 | $6.1M | −$419,000 | −6.45% |
| 2023 | 2023-12-31 | $6.5M | −$277,000 | −4.09% |
| 2022 | 2022-12-31 | $6.8M | $928,000 | +15.88% |
| 2021 | 2021-12-31 | $5.8M | $4.4M | +301.30% |
| 2020 | 2020-12-31 | $1.5M | $597,000 | +69.50% |
| 2019 | 2019-12-31 | $859,000 | — | — |
BridgeBio Pharma quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.1M | −$264,000 | −20.05% |
| Q1 2026 | 2026-03-31 | $1.2M | −$98,000 | −7.63% |
| Q4 2025 | 2025-12-31 | $1.4M | — | — |
| Q3 2025 | 2025-09-30 | $1.4M | −$140,000 | −9.10% |
| Q2 2025 | 2025-06-30 | $1.3M | −$257,000 | −16.33% |
| Q1 2025 | 2025-03-31 | $1.3M | −$312,000 | −19.55% |
| Q3 2024 | 2024-09-30 | $1.5M | −$101,000 | −6.16% |
| Q2 2024 | 2024-06-30 | $1.6M | −$63,000 | −3.85% |
| Q1 2024 | 2024-03-31 | $1.6M | −$37,000 | −2.27% |
| Q3 2023 | 2023-09-30 | $1.6M | −$6,000 | −0.36% |
| Q2 2023 | 2023-06-30 | $1.6M | $55,000 | +3.48% |
| Q1 2023 | 2023-03-31 | $1.6M | −$251,000 | −13.32% |
| Q3 2022 | 2022-09-30 | $1.6M | $1.4M | +520.75% |
| Q2 2022 | 2022-06-30 | $1.6M | −$1.9M | −54.62% |
| Q1 2022 | 2022-03-31 | $1.9M | $1.3M | +232.86% |
| Q3 2021 | 2021-09-30 | $265,000 | — | — |
| Q2 2021 | 2021-06-30 | $3.5M | — | — |
| Q1 2021 | 2021-03-31 | $566,000 | — | — |
BridgeBio Pharma depreciation and amortization trends
Over the last five fiscal years, BridgeBio Pharma's depreciation and amortization increased from $1.5M to $5.4M, a change of $4.0M. The latest reported quarter, Q2 2026, shows $1.1M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BridgeBio Pharma source filings ↗